Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.

ABSTRACT:

Rationale & objective

Some US hemodialysis (HD) facilities switched from oral cinacalcet to intravenous etelcalcetide as the primary calcimimetic therapy to control parathyroid hormone (PTH) levels after the introduction of etelcalcetide in 2017. Although clinical trials have demonstrated the superior efficacy of etelcalcetide versus cinacalcet, evidence comparing real-world effectiveness is lacking.

Study design

Prospective cohort.

Setting & participants

Patients receiving HD enrolled in US Dialysis Outcomes and Practice Patterns Study facilities.

Exposure

We classified HD facilities on the basis of whether >75% of calcimimetic users were prescribed etelcalcetide ("etelcalcetide-first") or cinacalcet ("cinacalcet-first") from March-August 2019.

Outcomes

SUBMITTER: Karaboyas A 

PROVIDER: S-EPMC9142674 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature